Panacea Index Logo

Command Palette

Search for a command to run...

Efficacy of Psychoactive Drugs for the Treatment of Posttraumatic Stress Disorder: A Systematic Review of MDMA, Ketamine, LSD and Psilocybin.

Journal of psychoactive drugs
May 5, 2021
Tracey Varker et al. (5 authors)
Journal ArticleSystematic ReviewResearch Support, U.S. Gov't, Non-P.H.S.Human Study
Study Details

Study Goal

The researchers aimed to examine the efficacy of LSD, among other substances, for treating PTSD in adults.

Results Summary

The study did not include any trials on LSD that met the inclusion criteria, so no results regarding LSD's effects were reported.

Population

Adults with PTSD (though no LSD-specific trials were included).

Effective Dosage

Not available

Duration

Not available

Interactions

None mentioned

Extracted Claims (3)
InterventionDirectionEndpointPopulationDosageImpactClaim #
ketamine
no change
treatment for comorbid PTSD and depression
adults
very low
ranked as very low evidence
#1
ketamine in combination with psychotherapy
no change
PTSD treatment
adults
low
ranked as low evidence
#2
MDMA in combination with psychotherapy
no change
PTSD treatment
adults
moderate
ranked as moderate evidence
#3
Abstract

The aim of this systematic review was to examine the efficacy of MDMA, ketamine, LSD, and psilocybin for the treatment of posttraumatic stress disorder (PTSD). A search of four databases for English language, peer-reviewed literature published from inception to 18th October 2019 yielded 2,959 records, 34 of which were screened on full-text. Observational studies and RCTs which tested the efficacy of MDMA, ketamine, LSD, or psilocybin for reducing PTSD symptoms in adults, and reported changes to PTSD diagnosis or symptomatology, were included. Nine trials (five ketamine and four MDMA) met inclusion criteria. Trials were rated on a quality and bias checklist and GRADE was used to rank the evidence. The evidence for ketamine as a stand-alone treatment for comorbid PTSD and depression was ranked "very low", and the evidence for ketamine in combination with psychotherapy as a PTSD treatment was ranked "low". The evidence for MDMA in combination with psychotherapy as a PTSD treatment was ranked "moderate".

Medical Subject Headings (MeSH)
HumansKetamineLysergic Acid DiethylamideN-Methyl-3,4-methylenedioxyamphetaminePsilocybinPsychotherapyPsychotropic DrugsStress Disorders, Post-Traumatic
Study Links
Quality Scores
SafetyNot Assessed
Quality75/10
Citation Metrics
Total Citations27
Citations/Year6.8
Relative Citation Ratio3.03
NIH Percentile85.2%
Research Impact Scores
APT Score0.75
Weight Score2.55
Normalized Score0.55
Related Supplements